www.sciencedirect.com by DominiqueBelpommeĀ & Philippe Irigaray
Much of the controversy over the cause of electrohypersensitivity (EHS) lies in the absence of recognized clinical and biological criteria for a widely accepted diagnosis. However, there are presently sufficient data for EHS to be acknowledged as a distinctly well-defined and objectively characterized neurologic pathological disorder. Because we have shown that 1) EHS is frequently associated with multiple chemical sensitivity (MCS) in EHS patients, and 2) that both individualized disorders share a common pathophysiological mechanism for symptom occurrence; it appears that EHS and MCS can be identified as a unique neurologic syndrome, regardless its causal origin. In this overview we distinguish the etiology of EHS itself from the environmental causes that trigger pathophysiological changes and clinical symptoms after EHS has occurred. Contrary to present scientifically unfounded claims, we indubitably refute the hypothesis of a nocebo effect to explain the genesis of EHS and its presentation. We as well refute the erroneous concept that EHS could be reduced to a vague and unproven āfunctional impairmentā. To the contrary, we show here there are objective pathophysiological changes and health effects induced by electromagnetic field (EMF) exposure in EHS patients and most of all in healthy subjects, meaning that excessive non-thermal anthropogenic EMFs are strongly noxious for health. In this overview and medical assessment we focus on the effects of extremely low frequencies, wireless communications radiofrequencies and microwaves EMF. We discuss how to better define and characterize EHS. Taken into consideration the WHO proposed causality criteria, we show that EHS is in fact causally associated with increased exposure to man-made EMF, and in some cases to marketed environmental chemicals. We therefore appeal to all governments and international health institutions, particularly the WHO, to urgently consider the growing EHS-associated pandemic plague, and to acknowledge EHS as a new real EMF causally-related pathology.
We have previously published evidence that a) electrohypersensitivity (EHS) is a distinct newly identified and objectively characterized neurologic pathological disorder which can be clinically diagnosed, and treated using peripheral blood and urine molecular biomarkers and cerebral imaging (Belpomme and Irigaray, 2020); b) EHS and Multiple Chemical Sensitivity (MCS) are possibly associated in EHS patients, both presenting similar clinical presentation and biological and radiological abnormal changes, therefore EHS and MCS could in fact be two etiopathogenic disorders of a unique common pathological syndrome (Belpomme et al., 2015, 2016); c) EHS and MCs are both associated with detectable low grade inflammation ((Belpomme et al., 2015) and oxidative stress (Irigaray et al., 2018a) with possible consequent blood brain barrier (BBB) opening (Belpomme and Irigaray, 2020) as in Alzheimer diseases (Heneka and O’Banion, 2007; Bell and Zlokovic, 2009; Erickson and Banks, 2013) and in other chronic pathological disorders (Patel and Frey, 2015) and d) EHS is associated with brain neurotransmitters abnormalities (Belpomme and Irigaray, 2020) as in laboratory animals exposed to man-made electromagnetic fields (EMF) (Hu et al., 2021)…
